Rehan Verjee
About Us
Current Events
Past Events
Video Gallery
Policy & Reports
Media Coverage
Contact Us
Rehan Verjee
Chief Executive Officer
Precede Biosciences

Rehan  is Chief Executive Officer of Precede Biosciences. Till recently, he was President of EMD Serono, Rehan lead the North American pharmaceutical operations of Merck KGaA, Darmstadt, Germany. EMD Serono’s approved medicines treat cancer, relapsing MS, infertility, and endocrine disorders.

As the Global Head of the Innovative Medicines franchises, Rehan led the specialty medicines effort globally across oncology and immune-mediated diseases. In this capacity, he worked with R&D to advance the most promising candidates through stages of clinical development, to acquire new medicines and technologies of strategic interest, to partner, to externalize candidates that would be best served by a different enterprise, and to enable introduction of new medicines into healthcare systems across the globe. Rehan co-chairs the global alliance with Pfizer for a PDx cancer immune therapy, drove creation of the alliance with GSK for a novel bi-functional fusion protein with potential across cancers where TGF-beta is thought to play a  determining role (a deal valued at up to 3.2BN EUR), and drove the acquisition of the Vertex DNA damage and response portfolio.

Rehan holds a master’s degree in Molecular and Cellular Biochemistry from the University of Oxford in the U.K, joining the company in 2004 and joining the management team in 2015 as an Executive Vice President and Chief Marketing and Strategy Officer. Rehan is a citizen of both Canada and Kenya.

© 2007 - USA India Chamber of Commerce Home | About us | Policy | Events | Photo Gallery | Awards | Membership | Media Coverage | Legal | Contact us